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Figure 1
reduced the effects and the results were comparable to the con-
trol (Table 1). The addition of NOC18 signiﬁcantly enhanced the
effects of osteogenesis.
Conclusions: The results of the current study tested the hy-
pothesis that ESWT signiﬁcantly promotes osteogenesis of bone
marrow stromal cells. These innovative ﬁndings at least in part,
explain some of the mechanism of ESWT in hip necrosis.
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Purpose: Hand osteoarthritis (OA) is a common rheumatologic
disease, with an estimated prevalence of 38% for women and
24.5% for men, aged over 66 years. The objective of this study is to
compare the efﬁcacy and tolerability of a topical form of ketoprofen
(Ketum® 2.5% gel) versus oral diclofenac in the treatment of hand
OA.
Methods: This randomized, double-blind, double-dummy multicen-
tre clinical trial was conducted in France by 64 general physicians
between March 2007 and May 2008. Eligible patients included
men and women between 45 and 75 years old, with symptomatic
hand OA diagnosed according to the criteria of the American
College of Rheumatology and presenting with a base-line visual
analogue scale (VAS) score >40 mm and a Dreiser score ≥5.
Patients were randomly assigned to treatment with ketoprofen gel
plus placebo oral capsules, or placebo gel plus oral diclofenac
capsules (150 mg/d). Clinical assessments were performed 3 and
7 days after the initiation of the treatment. The primary endpoint
was deﬁned as the change of VAS scores ( VAS) between base-
line and last assessment. The analysis of the primary endpoint in
the per-protocol (PP) population was set as the primary analysis.
[-8mm to +8mm] was set as the equivalence interval (95% CI).
The full analysis set (FAS) and the PP populations were deﬁned
a priori in the statistical analysis plan. 61 patients were eliminated
patients), to compliance issues.
from the FAS population (n=395) due, for most of them (46
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Ketum® 2.5% gel (N=164) Diclofenac per os (N=170) Statistical analysis
Change of VAS score* at 7 days (mm) (primary endpoint) -33.2±21.0 -36.9±21.0 [ -1.1 ; 7.4 ]
conﬁdence interval of adjusted difference
Change of VAS score at 3 days (mm) -19.7±14.4 -21.3±15.5 0.427 (P value of ANCOVA)
Change of Dreiser score** at 7 days -6.0±4.4 -6.4±4.4 0.190 (P value of ANCOVA)
Change of Dreiser score at 3 days -3.6±3.1 -3.7±3.2 0.568 (P value of ANCOVA)
PGA on last assessment Very efﬁcient: 26.4% Very efﬁcient: 33.5% p=0.304 (bilateral Wilcoxon test)
Efﬁcient: 36.8% Efﬁcient: 31.8%
Moderalety efﬁcient: 27.0% Moderalety efﬁcient: 25.9%
Not efﬁcient: 9.8% Not efﬁcient: 8.8%
Pain auto-evaluation*** 31.2±8.7 29.5±8.9 p=0.078 (bilateral Wilcoxon test)
Therapeutic index**** (physician’s assessment) 2.86±1.00 3.09±0.97 p=0.033 (bilateral Wilcoxon test)
*Score from 0mm (no pain) to 100mm (maximal pain). **Score between 0 (no functional disability) and 30 (maximal functional disability). ***Area under the curve of
pain auto-evaluation from day 1 until day 7. ****Ratio of efﬁcacy/tolerability, comprised between 0,25 (worst ratio) and 4 (best ratio).
Results: 395 patients, predominantly females (74%), with a mean
age of 61 years were included. At base-line, mean VAS score and
Dreiser score were 70 mm and 12.5, respectively. Both treatment
arms were comparable for all the patients’ characteristics. In the
FAS population,  VAS scores at the end of the treatment [0,4mm
to 8,5mm] was slightly outside the equivalence interval. Whereas,
in the PP population (n= 334), the result of primary endpoint
was [-1,1mm to 7,4mm], demonstrating equivalence of efﬁcacy
between Ketum® 2.5% gel and diclofenac per os. Equivalence
was also shown for the following secondary efﬁcacy endpoints: 
VAS scores at 3 days,  Dreiser scores at 3 and 7 days, patient
efﬁcacy global assessment (PGA) and pain auto-evaluation (see
table 1). In terms of tolerability, there was no signiﬁcant difference
between both treatment groups (p=0.108).
Conclusions: This present study shows that, in the PP population,
Ketum® 2.5% gel and diclofenac per os are equivalent in terms of
efﬁcacy for the treatment of hand OA. These results support that
Ketum® could be an alternative therapy to oral NSAID treatments.
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Purpose: To identify and discuss ﬁve of the challenges experi-
enced during the designing, planning and execution of a RCT for
cartilage repair, using the pivotal study for BST-CarGel® (a new
medical device being investigated for the repair of focal articular
cartilage lesions) as an example. To summarize some aspects of
the trial and of the preclinical work that preceded its design.
Methods: Five major challenges in the process of planning and
conducting a pivotal trial for cartilage repair processes were iden-
tiﬁed and summarized. The preclinical work as the basis to design
the trial is summarized. The basics of the currently ongoing inter-
national pivotal trial are presented, as well as a brief description
of the clinical use of the device.
Results: Major challenges were: Lack of regulatory trial historical
comparators for cartilage repair: There were almost no bench-
marks when the trial was designed. An FDA guidance was issued
only in July 07. Identiﬁcation of appropriate primary, secondary
and tertiary endpoints becomes difﬁcult. Lack of agreement on the
appropriate tools to measure outcomes: Pain as primary outcome
vs structure of the new tissue. No test presently is the gold stan-
dard for cartilage repair; patient relevant tests, designed for OA or
ligament reconstruction, based on subjective input are still used.
